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Abstract
Recent findings have revealed that gut microbiota plays a substantial role in modulating dis-
eases such as autism, rheumatoid arthritis, allergies, and cancer that occur at sites distant
to the gut. Athymic nude mice have been employed for tumorigenic research for decades;
however, the relationships between the gut microbiome and host’s response in drug treat-
ment to the grafted tumors have not been explored. In this study, we analyzed the fecal
microbiome of nonxenograft and xenograft nude mice treated with phytosaponins from a
popular medicinal plant,Gynostemma pentaphyllum (Gp). Analysis of enterobacterial repet-
itive intergenic consensus (ERIC)-PCR data showed that the microbiota profile of xenograft
mice departed from that of the nonxenograft mice. After ten days of treatment with Gp sapo-
nins (GpS), the microbiota of the treated mice was closer to the microbiota at Day 0 before
the implantation of the tumor. Data obtained from 16S pyrosequencing of fecal samples reit-
erates the differences in microbiome between the nonxenograft and xenograft mice. GpS
markedly increased the relative abundance of Clostridium cocleatum and Bacteroides
acidifaciens, for which the beneficial effects on the host have been well documented. This
study, for the first time, characterizes the properties of gut microbiome in nude mice re-
sponding to tumor implant and drug treatment. We also demonstrate that dietary saponins
such as GpS can potentially regulate the gut microbial ecosystem by increasing the number
of symbionts. Interestingly, this regulation of the gut ecosystemmight, at least in part, be re-
sponsible for or contribute to the anticancer effect of GpS.
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Introduction
Accumulated evidence shows that the efficacy of drug treatments varies greatly from individual
to individual, possibly influenced by the genetic polymorphism of individuals. It is also well
recognized that factors such as nutrition, age, overall health, and gut bacterial distribution, in-
fluence the drug metabolism of an individual. Normal gut microbes make significant contribu-
tions to the overall health of their host including protection against potentially harmful
microorganisms and stimulation of the immune system. Recent findings have revealed that gut
microbes play an even greater role in modulating human metabolic phenotypes and individu-
als’ drug responses. On the one hand, the host’s dietary and drug uptake can alter the gut
microbiota composition [1–3]. Conversely, microbes can influence the bioavailability and bio-
activity of ingested products, including functional foods and herbal medicines [4, 5] as well as
the host’s metabolic phenotypes [6]. Strikingly, accumulating evidence shows that the gut
microbiota can influence diseases found in organs or tissues distant from the gut, such as obesi-
ty [2, 3], diabetes [7, 8], autism [9, 10], rheumatoid arthritis [11], allergies [12, 13], and chronic
liver disease [14].
Recent studies have presented strong evidence showing that intestinal microbiota modulates
the efficacy of chemotherapy. For example, it was found that beta-glucuronidase in intestinal
microbiota contributes to the delayed diarrhea caused by the antitumor camptothecin deriva-
tive irinotecan hydrochloride (CPT-11) [15, 16]. Later study showed that mice tolerated higher
dosages of CPT-11 when the drug was administered together with a beta-glucuronidase inhibi-
tor [17]. Commensal intestinal microbiota might also play a prominent role in the develop-
ment and severity of chemotherapy-induced mucositis in cancer patients [18, 19]. Animal
studies have demonstrated that intestinal microbiota modulates the antitumor efficacy of cy-
clophosphamide, in part, through the induction of “pathogenic” Th17 cells [20]. Along this
line, a recent report has shown that disruption of commensal microbiota impairs the response
of subcutaneous tumors to CpG-oligonucleotide immunotherapy and platinum chemotherapy
[21]. In addition to their impact on chemotherapy, the gut microbiota has been suggested to
mediate the effect of diet or dietary compounds in cancer prevention and cancer risk. For in-
stance, a resveratrol-supplemented diet significantly reduced the colonic tumors in rats
through the reduction of bacterial glucuronidase [22]. A combination of beneficial microbes
and specific dietary compounds has been found to prevent the development of colonic polyps
in both animals and humans [23–25]. Overall, the dynamic interplay between the gut micro-
biota and ingested drugs or dietary compounds impacts on cancer risks and their treatment.
Athymic nude mice have been a major animal model for cancer research. Their impaired
immune system facilitates tumor grafting avoiding the risk of graft rejection by the animal’s
immune system. Early study of mouse gastrointestinal microecology showed that the loss of T-
cell function does not drastically alter the cultivable gut microbiota in Balb/c athymic (nu/nu)
mice as compared to heterozygous (nu/+) or thymus-implanted nude mice [26]. However, the
impact of grafted tumors on the gut microbiota in nude mice and how gut microbiome in turn
influence the host’s response to drug treatments have not been explored.
Saponins are found in many herbal and edible plants. Gynostemma pentaphyllum (Gp) has
been consumed as an herbal tea and used as a folk medicine dating back to the sixteenth centu-
ry, according to the Chinese Compendium of Materia Medica, where it is recommended for the
treatment of various diseases, including cancer. The main active components in Gp are triter-
penoid saponins [27]. In this study, we first demonstrate that GpS exert anticancer effects on
tumor-bearing nude mice. Using ERIC-PCR and 16S pyrosequencing methods, we compared
the gut microbiota compositions of nonxenograft and tumor-bearing xenograft nude mice, and
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investigated how GpS treatment could influence the composition of gut microbiota in healthy
and tumor-bearing nude mice.
Materials and Methods
Cell line and culture medium
Rat 6 (R6) cell line is a subclone of Fisher rat embryo fibroblasts derived from the primary rat
embryo cells in Freeman’s Laboratory [28]. The R6/GFP-ras cell line is a transformed clonal
cell line established from Rat 6 fibroblast cultures transfected by a GFP-tagged ras oncogene in
our laboratory [29]. Cells were grown in Dulbecco modified Eagle medium (DMEM) supple-
mented with 10% calf serum (Gibco, USA). Cultures were maintained in a humidified incuba-
tor at 37°C with 5% CO2 in air and incubated twice a week with fresh medium.
Animals and treatments
Experimental procedures were conducted according to guidelines for the care and use of labo-
ratory animals. All procedures were approved by the Baptist University Ethics Review Com-
mittee for Animal Research. Athymic nude mice (BALB/c-nu/nu) were purchased from the
Chinese University of Hong Kong and maintained in individually ventilated cages (IVC) on a
12-h light/12-h dark cycle, 20–22°C temperature and 40–60% humidity with free access to
food and water. Mice were fed with PicoLab Rodent Diet 20–5053 (LabDiet, USA). Xenograft
was performed by injecting 106 R6/GFP-ras transformed cells into the flank of each 7- to 8-wk-
old mouse. The control mice were injected with a volume of PBS solution equivalent to the
tumor volume. Tumors were blind-measured using an electronic caliper daily, and tumor vol-
ume was calculated using the formula (length × width2)/2. GpS extracted from the aerial parts
of Gynostemma pentaphyllum was purchased from Hauduo Natural Products (Guangzhou,
China). According to procedures outlined byWu et al. [30], each batch of GpS was authenticat-
ed and chemically profiled (S1 Fig). GpS was dissolved in 0.5% carboxymethyl cellulose (CMC)
at 50 mg/ml. A single dose of GpS at 750 mg/kg or solvent control was administered daily by
gavage and the treatment was initiated the second day after implanting the GFP-ras cells and
administered for 12 d. Six nonxenograft and six xenograft nude mice were used for investigat-
ing the impact of tumor implant on the gut microbiota. When determining the effects of GpS
on the gut microbiota, six animals each were used for both nonxenograft-control and nonxeno-
graft-GpS groups; while seven animals each were employed for xenograft-control and xeno-
graft-GpS groups. Euthanasia of animals was carried out according to the guidance of the
American Veterinary Medical Association (AVMA). Total 38 athymic nude mice were used in
the experiment, and carbon dioxide (CO2) inhalation was used for euthanasia of mice.
Fecal sample collection and bacterial genomic DNA extraction
Animal feces were collected from each mouse for two consecutive hours from 8:00 to 10:00 A.
M. on day 0 (before the xenograft), and day 5 and day 10 after GpS treatment. All fecal samples
were immediately stored at -20°C for later DNA extraction. Total genomic DNA was isolated
from fecal samples as described with a slight modification [31, 32]. In brief, fecal samples of a
weight of 0.1 g were vortexed in 4 ml of sterile PBS (pH 7.4) for 5 min, and then centrifuged at
40×g for 8 min to collect the upper phase containing the bacteria. After repeating this proce-
dure once, the supernatant was centrifuged at 2000×g for 8 min. The supernatant was dis-
carded and the bacterial pellets were washed twice with PBS to isolate the DNA. DNA
concentration was determined using NanoDrop 1000 spectrophotometry.
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ERIC-PCR
ERIC sequences are noncoding, highly conserved intergenic repeated sequences that reside in
the genomes of various bacterial species, including enterobacteria [33, 34]. ERIC-PCR was
used to profile gut microbiomes [35] by using fecal genomic DNA as the template and a pair of
ERIC specific primer sequences: ERIC 1R (5’-ATGTAAGCTCCTGGGGATTCAC-3’) and
ERIC 2 (5’-AAGTAAGTGACTGGGGTGAGCG-3’). The PCR reaction was optimized and de-
termined using an orthogonal array design. The 25 μl reaction mixture consisted of 5 μl 5×PCR
reaction buffer, 250 μM dNTP, 2 mMMg2+, 0.4 μM primers, 1.5 units Hotstart Taq polymer-
ase, and 50 ng fecal genomic DNA. PCR was performed as follows: 94°C for 5 min, followed by
35 cycles of 95°C for 50 s, 49°C for 30 s, 46°C for 30 s, 72°C for 3 min, and then a final exten-
sion at 72°C for 9 min [36]. 10 μl of each PCR product was loaded on 2% (w/v) agarose gels
containing 0.5 μg/ml ethidium bromide and run for 40 min at 100 V. A DNA ladder (0.1–10.0
kb) was used as the DNA size marker (NEB, N3200). Agarose gels were photographed using
the Gel Doc XR+ system.
Data analysis of ERIC-PCR fingerprints
Partial least squares discriminant analysis (PLS-DA) was performed to visualize the dynamic
changes of microbiota composition before and after treatments. The banding patterns of
ERIC-PCR products were digitized by Image Lab 3.0 system (Bio-Rad) to generate the data
based on the sum of the distance and the intensity of each DNA band within each sample lane.
The scores were subjected to PLS-DA plot using SIMCA-P 12.0 tool (Umetrics, Umea, Sweden)
for which the confidence level was set at 95% (P<0.05). The correlation coefficient was calcu-
lated and used to assess the correlation between the two samples applying the CORREL func-
tion in Microsoft Office Excel 2003.
16S rRNA gene pyrosequencing of fecal DNA samples
Three fecal samples randomly picked from each experimental group on Day 10 were subjected
to further analysis by using 16S rRNA gene pyrosequencing. Pyrosequencing was conducted
on the 454 Sequencer (Junior System) (Life Sciences Corp., USA). To begin, PCR was per-
formed on each sample in a final reaction volume of 25 μl consisting of 0.1–2 μl DNA, 300 nM
of each primer (563F and 1064R of the 16S rRNA gene), 2.5 μl 10x Expand High Fidelity buffer
(Roche), 200 μM PCR Grade Nucleotide Mix, and 2.6 units of the Expand High Fidelity En-
zyme mix (Roche). The reaction volume was adjusted using Milli-Q H2O. The forward primer
of each reaction was assigned a unique 11-nt barcode, then PCR was conducted with an initial
denaturation at 94°C for 2 min, followed by 35 cycles of 94°C for 15 s, 58°C for 20 s, and 72°C
for 1 min. An elongation reaction for 7 min at 72°C was finally performed, followed by cooling
at 4°C until collection. Amplicon sizes were confirmed on 1% agarose gel and purified using
the PureLink Quick Gel Extraction Kit (Life Technologies). Amplicon libraries were quantified
using the Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies) with a FLUOstar OPTI-
MA F fluorometer (BMG Labtech GmbH, Offenburg, Germany), and visually assessed using
the FlashGel System (Lonza Group Ltd., Basel, Switzerland). Emulsion-PCR and pyrosequen-
cing using titanium chemistry on the GS Junior System (454 Life Sciences Corp., Branford, CT,
USA) was conducted according to manufacturer instructions.
Denoising and analysis of pyrosequencing data
The Quantitative Insights into Microbial Ecology (QIIME) software package version 5.0 was
used to process and analyze the raw pyrosequencing data [37]. Pyrosequencing data was first
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processed using QIIME and filtered for quality by removing sequences that were shorter than
200bp or longer than 1kb with a quality score below 25, or that contained primer mismatches,
uncorrectable barcodes, or had a homopolymer run, or had more than 6 ambiguous bases. The
operational taxonomic units (OTUs) in QIIME are clusters of sequences; these are used to rep-
resent taxonomic relatedness. Denoising raw sequences was done to reduce the number of
OTUs. Sequences from all samples were clustered into OTUs based on their similarity. The
denoised sequences were assigned to OTUs with a 97% identity threshold, and the most abun-
dant sequence from each OTU was selected as a representative sequence. Taxonomy was as-
signed to the OTUs by using the Basic Local Alignment Search Tool (BLAST). For tree-based
analyses, PyNAST was used to align the representative sequences of each OTU, and the Fas-
tTree algorithm was used to build a phylogenetic tree [38]. The differences in overall micro-
biota composition between compared samples were determined using the unweighted UniFrac
metric. The raw 454 pyrosequencing data were deposited in NCBI's Sequence Read Archive
(SRA) database under accession number of SRP052560.
The linear discriminant analysis (LDA) effect size (LEfSe) method [39], which is an algo-
rithm for high-dimensional class comparisons with a particular focus on metagenomic analy-
sis, was further applied to evaluate the key phylotypes responsible for the differences between
microbial communities by using the processed data from QIIME. LEfSe uses LDA scores to es-
timate the effect size of each differentially abundant feature, and to rank the relative difference
of microbial taxa that are discriminative with biological consistency and statistical significance.
The alpha value used for the algorithm of LEfSe was internally set at 0.05, which corresponded
to 95% confidence level (P<0.05) to detect features with significant differential abundance and
to test the biological consistency. The OTU network was generated using QIIME and was visu-
alized using Cytoscape. The Shannon-Wiener diversity index (H') was used to evaluate the di-
versity of the microbial communities. A Venn diagram was used to depict the unique and
shared taxa among microbial communities.
Statistical analysis
The data are presented as mean ± SEM, and statistical comparisons were performed using one-
way ANOVA followed by Dunnett’s post test with the GraphPad Prism version 5.00 (Graph-
Pad Software, San Diego, CA, USA) or Student’s t-test at P values of<0.01() or<0.05().
Results
Significant alteration in the gut microbiota of xenograft nude mice
To investigate whether a tumor implanted in the flank of a mouse would affect microbiota in
the gut, fecal samples were collected from mice at Days 0 (before tumor cells or saline injec-
tion), 5 and 10. Meanwhile, the tumor volume and body weight of mice were recorded during
the entire experimental period (Fig 1A and 1B). The fecal microbial profiles were analyzed
using ERIC-PCR. The banding patterns of ERIC-PCR (Fig 1C) were then digitized using the
Image Lab 3.0 system (Bio-Rad) and analyzed using PLS-DA analysis (Fig 1D). Although
inter-animal variation in microbial profile appeared at Day 0, a clear separation between the
samples from Day 10 normal and tumor-bearing mice appears in the PLS-DA plot (Fig 1E)
and in the correlation coefficient plot (Fig 1F). These findings suggest that the xenografted tu-
mors caused alteration of gut microbiota composition as compared to the nonxenograft mice.
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GpS inhibited tumor growth in nude mice
In our previous study, GpS demonstrated strong anti-cancer effect against the growth of R6/
GPS-ras transformed cells at nontoxic dosages (unpublished data). To assess the effect of GpS
on the xenografted tumors, parallel sets of nonxenograft and xenograft nude mice were given
single daily doses of GpS (750 mg/kg) by gavage, initiated on the second day after implant of
the transformed R6/GFP-ras cells. The tumor volume and tumor weight of the GpS-treated
group were 60% and 50%, respectively, lower than the untreated group (Fig 2A and 2B). No
weight loss was observed in the experimental animals (Fig 2C). There was no observable dam-
age of internal organs of the treated animals. These results echo the previous report on the
chronic toxicity studies of Gp where the rodents were treated 750 to 1000 mg/kg for long dura-
tion of time [40, 41]. From these GpS-treated mice, fecal samples were collected for subsequent
analysis and comparison with the non-treatment groups.
GpS treatment induced unique alteration of microbiota in xenograft, but
not in nonxenograft mice
Fecal samples collected from the above four experimental groups—nonxenograft and xenograft
nude mice with and without GpS treatment—at Days 0, 5, and 10 were subjected to ERIC-PCR
analysis. The PLS-DA plots, based on the ERIC-PCR banding patterns of the fecal DNA sam-
ples, showed no clear difference between samples collected in the presence or absence of GpS
in nonxenograft mice (Fig 3A and 3B). In the xenograft mice, by contrast, clusters of samples
collected from different time points were observed, where Day 0 samples were mainly located
in the right quadrant (Fig 3C and 3D). Intriguingly, after treatment, the Day 10 samples from
the GpS-treated xenograft mice appeared in the right lower quadrant overlapping with Day 0
group (Fig 3D). On the other hand, the samples collected from the untreated mice gathered in
the left quadrant away from the Day 0 control (Fig 3C).
16S pyrosequencing further revealed marked differences between
nonxenograft and xenograft nude mice in microbial communities
To further examine the detailed composition of the fecal microbiome of the experimental ani-
mals, we randomly selected three fecal DNA samples collected on Day 10 from each of the four
experimental groups, namely the nonexenograft mice with and without GpS treatment; and
the xenograft mice with and without GpS treatment, and performed 16S rRNA gene pyrose-
quencing. A total of 147,128 reads passing quality control were produced in this study, with an
average of 12,261 sequences per sample. A total of 399 distinct OTUs were determined after
denoising using QIIME [37].
We first compared the fecal microbiome of the nonxenograft and xenograft mice without
the influence of GpS. The OTU network analysis clearly separated the nonxenograft from the
xenograft mice, suggesting that tumor growth was the likely cause of the differences in fecal
microbiota composition (Fig 4A). Nonxenograft and xenograft mice had 112 and 91 unique
OTUs, respectively, and shared 110 OTUs. Xenograft mice exhibited reduced microbial
Fig 1. Comparison of fecal microbiota between nonxenograft and xenograft nudemice. (A) Tumor growth curve. (B) Body wight. (C) Representative
ERIC-PCR DNA fingerprints of the fecal microbiota of individual nonxenograft and xenograft nude mice. Fecal samples were collected before xenograft (Day
0), and 5 & 10 d upon saline or tumor cells injection. (D) Digitization of ERIC-PCR DNA fingerprints. Gel images were digitized by Image Lab 3.0 system (Bio-
Rad). The peak area corresponded to the intensity of ERIC-PCR band shown in the gel image. (E) PLS-DA plot of ERIC-PCR data from fecal microbiota of
nonxenograft and xenograft nude mice at Day 10. Black square: nonxenograft nude mice; Red dot: xenograft nude mice. (F) Correlation coefficients of fecal
microbiota of nonxenograft and xenograft nude mice. All data were expressed as the percentage change over the Day 0 control of each mouse, and
presented as the mean ± SEM (* P < 0.05, ** P < 0.01 versus nonxenograft group, n = 6/group).
doi:10.1371/journal.pone.0126807.g001
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diversity compared with nonxenograft mice based on the calculated Shannon-Wiener diversity
index (Fig 4B).
The 16S pyrosequencing data were analyzed using LEfSe to identify the key phylotypes re-
sponsible for the differences in fecal microbiota composition between the nonxenograft and xe-
nograft mice. As shown in Fig 4C, the taxonomic distribution of fecal microbiota between the
two groups varied significantly at all taxonomic levels. At the phylum level, the most differen-
tially abundant bacterial taxon in the feces of nonxenograft mice was TM7, whereas Bacteroi-
detes was overrepresented in xenograft mice. Compared with the nonxenograft mice, the
Fig 2. Effect of GpS on tumor growth in nudemice. (A) Tumor volume, (B) Tumor weight and (C) Body
weight. Xenografting was performed by injecting 106 R6/GFP-ras transformed cells into the flank of each 7- to
8-wk-old mouse. A single dose of GpS at 750 mg/kg or solvent control was administered daily by gavage and
the feeding was initiated the second day after implanting the GFP-ras cells. All data are presented as the
mean ± SEM (* P < 0.05, ** P < 0.01 versus control) (n = 7/group).
doi:10.1371/journal.pone.0126807.g002
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xenograft mice had relatively high levels of Deltaproteobacteria, but low levels of Gammapro-
teobacteria, both of which are Gram-negative proteobacteria.Mollicutes, in the phylum Teneri-
cutes, were also underrepresented in xenograft mice. The histogram of the LDA scores (Fig 4D)
and the relative abundance scores (Fig 4E) further illustrated a clear difference between the
nonxenograft and xenograft mice in the composition of biologically clades. Several clades in
the phylum Firmicutes, such as Catabacteriaceae, Peptococcaceae, and Coprococcus, were par-
ticularly abundant in nonxenograft but not in xenograft mice (Fig 4E).
Xenograft and nonxenograft mice responded differently to GpS
treatment
To view in detail the impact of GpS treatment on gut microbiota, we took the 16S pyrosequen-
cing data from the above four experimental groups and analyzed the phylogenic compositions
of fecal samples using LEfSe. The taxonomic data are displayed as cladograms in Fig 5. In the
nonxenograft group, the classes of Clostridia andMollicutes were found to be particularly dif-
ferentially abundant (Fig 5A). Within Clostridia, families such as Catabacteriaceae,
Fig 3. ERIC-PCR analysis of the effect of GpS on fecal microbial composition of nudemice. PLS-DA plots of (A) untreated nonxenograft mice, (B)
GpS-treated nonxenograft mice, (C) untreated xenograft mice, and (D) GpS-treated xenograft mice.
doi:10.1371/journal.pone.0126807.g003
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Fig 4. Pyrosequencing analysis of fecal microbiota of nonxenograft and xenograft nudemice. (A) Comparisons of overall OTU networks of fecal
microbiota between the nonxenograft (red) and xenograft (green) mice. (B) Shannon-Wiener diversity index (H'). The analysis is based on the percentage of
classified OTUs of each sample. H' index was used to calculate the diversity of microbial communities. H' = ∑ - (Pi * ln Pi). (C) Taxonomic representations of
fecal microbiome of nonxenograft and xenograft nude mice. The differentially abundant taxa are presented with designated colors using LEfSe method. The
taxa from nonxenograft and xenograft mice are colored in red and green, respectively. The taxa with nonsignificant changes between the nonxenograft and
xenograft mice are colored in yellow. Each small circle’s diameter represents the taxon abundance. (D) Histogram of the LDA scores of fecal 16S rRNA gene
sequences of nonxenograft (red color) and xenograft (green color) mice. LDA scores characterized the magnitude of differential abundance in the microbial
Regulation of Gut Microbiota by Herbal Saponins
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Peptococcaceae, and Ruminococcaceae, and genera such as Clostridium, Coprococcus, and Oscil-
lospira, were all found to be more abundant in the untreated nonxenograft mice than in the
GpS-treated mice. Within the classMollicutes in the phylum Tenericutes, lineages including
Anaeroplasmatales, Anaeroplasmataceae, and Anaeroplasma were the prevalent clades in the
nonxenograft group without GpS treatment (Fig 5B). Anaerotruncus, a genus in Clostridia, was
the only differentially abundant taxon detected in the treated mice (Fig 5C).
In the xenograft mice, three dominant phyla showed differential responses to GpS treat-
ment: Firmicutes, Proteobacteria, and Tenericutes. Within these phyla, Clostridia, Betaproteo-
bacteria, and Erysipelotrichi were the predominant classes, respectively. The control and GpS-
treated mice exhibited different portions of Clostridia (95.84% vs. 49.08%), Betaproteobacteria
(0.81% vs. 8.01%) and Erysipelotrichi (1.65% vs. 39.58%) (Fig 5D). Differences in bacterial com-
munity structure between the control and GpS-treated mice were also observed. In the GpS-
treated xenograft mice, two lineages were notably high in relative abundance compared with
the controls: the Proteobacteria-Betaproteobacteria-Burkholderiales-Alcaligenaceae lineage and
the Tenericutes-Erysipelotrichi-Erysipelotrichales-Erysipelotrichaceae-Clostridium lineage (Fig
5D). At the family level of these two particular lineages, GpS-treated xenograft mice showed
higher levels of Alcaligenaceae (8.01% vs. 0.81%) and Erysipelotrichaceae (39.58% vs. 1.65%)
compared with the control. At the genus level, Clostridium presented the greatest difference in
abundance between the two groups (Fig 5F). Clostridium constituted less than 0.5% of total
bacteria in controls, but was more prevalent in GpS-treated mice (mean 38.48%). We then fur-
ther compared the differentially abundant bacterial populations between the nonxenograft and
xenograft groups treated with GpS (Fig 5G and 5I). However, the relative abundance of identi-
fied taxa was all less than 0.01%, indicating the differences were not so striking between the
two groups.
To identify which taxa were unique to different treatment groups, we compared the bacteri-
al families using the Venn diagram. As shown in Fig 6, there were seven and two unique bacte-
rial families found in the nonxenograft and xenograft mice, respectively, whereas 19 bacterial
families appeared in both groups. Comparing nonxenograft mice with and without GpS treat-
ment, 22 bacterial families were shared, whereas the control and GpS-treated groups each had
4 unique bacterial families. By contrast, in xenograft mice, 20 bacterial families were found in
both the control and GpS-treated mice. Only one unique bacterial family was found in the con-
trol whereas 6 unique families were found in the GpS-treated xenograft mice. These unique
bacterial families with a mean relative abundance> 0.01% are listed in Fig 6.
Two beneficial bacterial species were markedly enhanced by GpS
treatment
The consensus lineage map of OTUs generated by QIIME enabled bacterial identification at
the genus level, and in some cases, at the species level. Two of the OTUs related to Clostridium
cocleatum and Bacteroides acidifaciens were identified. In both xenograft and nonxenograft
mice, these species increased in number following GpS treatment. GpS-treated nonxenograft
mice showed 28 times higher levels of C. cocleatum, compared to the control mice. In the GpS-
treated xenograft mice, C. cocleatum was elevated 80 times above those found in the control
group. The relative abundance of B. acidifaciens increased five-fold compared with the untreat-
ed controls (Fig 7B). We further analyzed the data in a PLS-DA model and plotted the WC
taxa between compared samples. (E) The relative abundance (%) of differentially abundant families and genera. Nonxenograft nude mice, n = 3; Xenograft
nude mice, n = 3. Data are presented as the mean ± SEM (* P < 0.05, ** P < 0.01, nonxenograft versus xenograft group).
doi:10.1371/journal.pone.0126807.g004
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loading plots using SIMCA-P, which measures the level of contribution of each variable in the
segregation of microbial composition upon treatment. As shown in Fig 7C, OTU #281 (C.
cocleatum) was farthest away from the axes, indicating its strongest level of contribution. The
substantial increase of C. cocleatum appeared to be an important contributor of fecal bacterial
community structures in GpS-treated tumor-bearing mice.
Discussion
The athymic nude mouse is the animal model most often used for tumorigenic studies. While
many aspects of the tumor-bearing mice’s physiology have been explored, the impact of the
grafted tumors on the gut microbiota in nude mice and how gut microbiota would influence
the drug responses of the hosts are unexplored. This study presents an investigation on how
gut microbiota in nude mice is influenced by the xenografted tumor and by the dietary and me-
dicinal saponins that exert anti-cancer effect under nontoxic dosages. ERIC-PCR and 16S pyro-
sequencing data demonstrated dynamic responses of intestinal microbial communities to
tumor grafting in the presence or absence of GpS-treatment.
Early reports on the gastrointestinal microecology of Balb/c nude mice suggested that the
lack of a thymus did not significantly affect the normal microbial flora of the mouse [26]. Stud-
ies also cited the presence of activated macrophages upon stimulations with exogenous factors,
indicating that there might be intracellular components linking the tumor cells to the host flora
Fig 5. LEfSe analysis of pyrosequencing data obtained from different experimental groups. Effects of
GpS on fecal microbiome in nonxenograft (A-C) and xenograft (D-F) nude mice. Data are presented as the
mean ± SEM (* P < 0.05, ** P < 0.01, versus control group, n = 3/group). (G) to (I): comparison of
differentially abundant bacterial populations between the nonxenograft and xenograft groups treated with
GpS, data are presented as the mean ± SEM (* P < 0.05, xenograft versus nonxenograft group, n = 3/group).
(A), (D), & (G): taxonomic representations of fecal microbiome. (B), (E), & (H): histograms of the LDA scores
for differentially abundant clades. (C), (F), & (I): the relative abundance of differentially abundant families
and genera.
doi:10.1371/journal.pone.0126807.g005
Fig 6. Unique fecal bacterial families identified from different treatment groups. Venn diagram showing the number of unique and shared bacterial
families of nonxenograft and xenograft nude mice, with or without GpS treatment. Yellow: nonxenograft nude mice; Green: xenograft nude mice; Blue:
nonxenograft nude mice with GpS treatment; Red: Xenograft nude mice with GpS treatment. The table indicates the unique families to each treatment group
(n = 3/group).
doi:10.1371/journal.pone.0126807.g006
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through the host immune system [42]. In fact, gut microbiota is mobile. Alterations in anatom-
ical location, in addition to the composition, of the intestinal commensal bacteria are associated
with numerous chronic diseases [2, 43]. Significant alteration of intestinal microbial composi-
tion in tumor-xenografted mice treated with the anticancer agent cyclophosphamide has also
been reported in a very recent study [20]; these results are consistent with our observation. Our
results may indicate that tumor progression might lead to dysregulation of the host’s immune
system, which in turn could account for the alteration in gut microbiota of the xenografted
mice.
ERIC-PCR has been used to detect bacterial species in the Enterobacteriaceae and Vibriona-
ceae families, including well-known organisms such as Escherichia coli, Salmonella enterica,
Yersinia pestis, and Vibrio cholera. ERIC primer sequences have also been found in the genome
of various bacterial species [33, 34]. We observed that tumor growth rapidly altered the compo-
sition of gut microbiota (Fig 1). Intriguingly, as the tumor gradually shrank in response to GpS
treatment, the microbiota more closely resembled populations in the guts of animals before
Fig 7. Differentially abundant bacterial species responding to GpS treatment. (A) OTU heatmap based on the 16S rRNA gene reads identified bacterial
species. The figures displayed in the OTU heatmap are the raw OTU counts of individual mouse sample. p: phylum; c: class; o: order; f: family; g: genus; s:
species. (B) The relative abundance of Clostridium cocleatum and Bacteroides acidifaciens in nonxenograft and xenograft nude mice with or without GpS
treatment. Data are presented as the mean ± SEM (n = 3/group). (C) PLS-DAW*C loading plots. The data of relative abundance of identified bacterial
species was subjected to PLS-DA and generate W*C loading plots by SIMCA-P software. TheW*C loading plots was used to measure the degree of
contribution of each identified OTU in the segregation of microbial composition upon treatment.
doi:10.1371/journal.pone.0126807.g007
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implantation of the tumor cells (Fig 3D). This phenomenon was not observed in nonxenograft
mice receiving the same GpS treatment. Such alterations in microbiota composition demon-
strate a dynamic interaction of the gut microbes, the tumor-bearing host and the ingested phy-
tosaponins. Whether this change was the result of tumor regression or it was the result of GpS
treatment requires further investigation. Saponins exhibit many biological and pharmacologi-
cal effects, however, one of the known traits of saponins is the poor bioavailability [44]. Wheth-
er part of effects of saponins lie on the interplay between the gut lumen and the microbiota is
of interest to be explored in the future.
Fecal microbial communities were assessed using 16S pyrosequencing to obtain a compre-
hensive profile. At the phylum level, Tenericutes, Proteobacteria, and Bacteroidetes were more
abundant in GpS-treated mice than in the controls, whereas Firmicutes showed the opposite
pattern, being less abundant in GpS-treated mice, particularly in tumor-bearing mice. A shift
in the ratio between Firmicutes and Bacteroidetes has been reported in many other studies, and
such a shift has been linked to numerous diseases, such as obesity [2, 3]. The pyrosequencing
data indicated that the Bacteroidetes/Firmicutes ratio showed an increasing trend after 10 d of
GpS treatment in xenograft mice. GpS treatment also increased the relative abundance of Pro-
teobacteria, the major group of Gram-negative bacteria in the gut. The lipopolysaccharide
(LPS) in the outer layer of the Gram-negative bacteria is known to stimulate the immune sys-
tem and has been recognized as a treatment for cancer [45]. The increased numbers of Proteo-
bacteria in GpS-treated mice might enhance the secretion of LPS, thus activating an immune
response against tumor growth, directly or indirectly.
The pyrosequencing analysis has identified several species of bacteria responding to GpS
treatment as indicated in Fig 7A. Two species C. cocleatum and B. acidifaciens, which have sev-
eral well-documented beneficial effects, were markedly increased in both nonxenograft and xe-
nograft mice treated with GpS (Fig 7B and 7C). A previous study indicated that a strain of C.
cocleatum protects against the colonization of the gut by the pathogenic Clostridium difficile,
revealing multiple glucosidase activities that might degrade the oligosaccharide chains of
mucin in the digestive tract [46]. C. cocleatum has been shown to be significantly decreased in
irritable bowel syndrome patients [47, 48]. C. cocleatum also plays a role in the metabolism of
diglucoside, and has a deglycosylation function [49]. Clostridium bacteria are a major compo-
nent of mammalian gut microbiota and are responsible for promoting antiinflammatory im-
mune responses. We speculate that C. cocleatum, which increased considerably in GpS-treated
xenograft mice, is responsible for most of the differences between the GpS-treated xenograft
mice and the controls. In addition to the above-mentioned well-documented beneficial effects,
C. cocleatummay play a role similar to symbionts by taking part in the metabolism of Gp sapo-
nins by enhancing the glucosidase activities.
B. acidifaciens was first isolated from the cecum of mice [50]. B. acidifaciens and its close rel-
ative, B. uniformis, were found to be associated with the degradation of isoflavones in human
feces [51]. A recent study demonstrated that B. acidifaciens promoted IgA production [52]. It
is reasonable to postulate that the beneficial effects of C. cocleatum and B. acidifaciens support
the anticancer effects of GpS. Changes in gut microbiota were more apparent in GpS-treated
xenograft mice than in GpS-treated nonxenograft mice; that is, the pathological conditions of
the xenograft enhanced the effects of GpS treatment. Besides C. cocleatum and B. acidifaciens,
the change of OTU #496, an undefined species named Pei061, is also notable. However, the in-
formation of Pei061 is very limited based on current literature retrieval.
In summary, our results indicated that grafted tumors can significantly alter the composi-
tion of gut microbiota, indicating an active interaction between gut flora and the tumor-bear-
ing host. We also demonstrated that GpS tends to modulate the gut microbiota by boosting
levels of beneficial bacteria. Findings also showed much wider changes in phylogenic
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composition after GpS treatment in the tumor-bearing than in the healthy nude mice. At this
point, the mechanism that accounts for these observations is unclear. Whether this alteration
of gut microbiota induced by GpS treatment is linked to the anticancer effect of GpS treatment
warrants further investigation. Nevertheless, this study provides fundamental information for
understanding how gut microbiota in one mammal changes in response to tumors and to an
anti-tumor agent. These findings have broader, significant implications for understanding the
role of gut microbiota in both disease and treatment.
Supporting Information
S1 Fig. Quality control of GpS. The GpS contains about 85 to 88% of triterpenoid saponins
determined by silica gel thin-layer chromatography (TLC). The ginsenoside Rb1 was used as a
titration standard. Each batch of GpS was first generated a UPLC profile, and then compared
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